CONFOGEN
LIVE

Serial Number

79404957

Owner

Confo Therapeutics NV

Attorney

Jessica S. Sachs

Filing Date

Jul 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CONFOGEN Trademark

Serial Number: 79404957 • Registration: 7877158

CONFOGEN is a trademark filed by Confo Therapeutics NV on July 9, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Confo Therapeutics NV (3 trademarks)

Technologiepark 30

Entity Type: 99

Confo Therapeutics N.V. (10 trademarks)

Technologiepark,

Entity Type: 98

Trademark Details

Filing Date

July 9, 2024

Registration Date

August 5, 2025

Published for Opposition

June 17, 2025

Goods & Services

Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with g protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines.

Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs).

Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management.

Pharmaceutical and veterinary preparations for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteins, namely, small molecules and antibodies for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; veterinary products, namely, antigens and reagents for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 5, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 15, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 15, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 5, 2025 FICR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Aug 12, 2025 CORR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 5, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 5, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 14, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 12, 2025 TROA
REFUSAL PROCESSED BY IB
Apr 5, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 16, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 15, 2025 RFRR
CORRECTION TRANSACTION RECEIVED FROM IB
Feb 14, 2025 CRCV
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2025 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2025 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Feb 6, 2025 RFWR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jan 31, 2025 ADCH
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 1, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 31, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 30, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 27, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 27, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 26, 2024 REPR